Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Hexal
INDICATIONS [/za_1104.html#1] [/za_1104.html#1] [/za_1104.html#1] CONTRA-INDICATIONS [/za_1104.html#1] [/za_1104.html#1] DOSAGE [/za_1104.html#1] [/za_1104.html#1] SIDE-EFFECTS [/za_1104.html#1] [/za_1104.html#1] [/za_1104.html#1] PREGNANCY [/za_1104.html#1] [/za_1104.html#1] OVERDOSE [/za_1104.html#1] IDENTIFICATION [/za_1104.html#1] [/za_1104.html#1] PATIENT INFORMATION FLUVOXAMINE-HEXAL™ 100 MG FILM COATED TABLETS SCHEDULING STATUS: S5 PROPRIETARY NAME (and dosage form): FLUVOXAMINE-HEXAL™ 100 MG FILM COATED TABLETS COMPOSITION Each 100 mg tablet contains FLUVOXAMINE maleate (5-methoxy-4’-(trifluoromethyl)valerophenone(E)-O-(2-aminoethyl)- oxime maleate (1:1)) 100 mg PHARMACOLOGICAL CLASSIFICATION A.1.2 Psychoanaleptics (antidepressants) PHARMACOLOGICAL ACTION The mechanism of action of fluvoxamine is presumably linked to its serotonin re-uptake inhibition in brain neurons. PHARMACOKINETICS: Fluvoxamine is variably absorbed after oral administration. Bioavailability is about 50%. Fluvoxamine is extensively metabolised in the liver. The metabolites are pharmacologically inactive and are renally excreted. The elimination half- life is 15 to 20 hours. Steady state plasma levels are reached within 2 weeks of treatment with a constant dose. INDICATIONS • FLUVOXAMINE-HEXAL is indicated for the treatment of major depressive disorders and for short-term treatment of severe, disabling obsessive-compulsive disorders, where the obsessions or compulsions significantly interfere with social or occupational functioning, cause severe distress or are time-consuming. CONTRA-INDICATIONS • Hypersensitivity to fluvoxamine or any of the ingredients of FLUVOXAMINE-HEXAL • MAO INHIBITORS: FLUVOXAMINE-HEXAL should not be used in combination with MAO inhibitors or within 2 weeks of terminat Read the complete document